StocksMedium•4 November 2026•
1 min read
Evommune Enters $30 Million Private Placement Agreement
Key Facts
1Evommune entered into a securities purchase agreement to sell 4,966,889 shares of common stock to healthcare institutional investors.
2The purchase price for each share of common stock in the private placement is set at $6.0.
Evommune entered into a securities purchase agreement to sell 4,966,889 shares of common stock to healthcare institutional investors, Business Wire reported. The private placement is valued at $30 million, with the purchase price for each share set at $6.0.
The clinical-stage biotech company is raising this capital to fund its development of therapies for chronic inflammatory diseases. Regarding market performance, EVMN closed at $5.94 on November 3, 2026, slightly below the designated private placement price.